Methotrexate reduces withdrawal rates of TNF inhibitors due to ineffectiveness in rheumatoid arthritis but only in patients who are seropositive

Article info

Letter

Mandy Greenwood Centre for Rheumatology, UCL, London, UK PubMed articles Google scholar articles
Muhammad Shipa Centre for Rheumatology, UCL, London, UK PubMed articles Google scholar articles
Su-Ann Yeoh Centre for Rheumatology, UCL, London, UK PubMed articles Google scholar articles
Euthalia Roussou Rheumatology Department, Barking Havering and Redbridge University Hospitals NHS Trust, Romford, Essex, UK PubMed articles Google scholar articles
Dev Mukerjee Rheumatology Department, North Middlesex University Hospital NHS Trust, London, UK PubMed articles Google scholar articles
Michael R Ehrenstein Centre for Rheumatology, UCL, London, UK PubMed articles Google scholar articles

Correspondence to Professor Michael R Ehrenstein, Centre for Rheumatology, UCL, London WC1E 6JF, UK; m.ehrenstein{at}ucl.ac.uk

Citation

Greenwood M, Shipa M, Yeoh S, et al

Methotrexate reduces withdrawal rates of TNF inhibitors due to ineffectiveness in rheumatoid arthritis but only in patients who are seropositive

Annals of the Rheumatic Diseases 2020;79:1516-1517.

Online issue publication

May 12, 2021